Not Applicable
The present invention generally relates to methods for manufacturing microneedle structures.
Microneedle-based electrochemical biosensor devices have witnessed increased development activity in recent years and rely on the interaction between an electrical signal and a biological analyte. However, to serve useful purposes, these devices must be fabricated using design topologies that are compatible with existing packaging methods. In this vein, current chip-scale implementations of microneedle biosensors (and drug delivery actuators, for that matter) require wire-bonding or flip-chip methods of establishing electrical contact with the active sensing (or transducing) element located on or within the microneedle structure. In spite of this approach, wire bonding and flip-chip methods are not compatible with useful embodiments of sensing/therapeutic capabilities as these modalities would serve to obstruct the microneedle surface and prevent reliable penetration of the stratum corneum. The current methodology allows for an alternative to wire-bonding and flip-chip methods of electrical interface by means of circumscribing electrically-conductive microneedles with an insulating barrier to facilitate a spatially-defined region that can be probed on the posterior surface of the substrate on which the microneedle elements are located.
Microneedle-based electrochemical biosensors represent a promising avenue towards the minimally-invasive quantification of a number of relevant analytes in the physiological fluid, such as interstitial fluid, blood, serum, and plasma. In such devices, an electrical signal is applied to the surface of a microneedle, which concomitantly instigates an electrochemical reaction to either oxidize or reduce an analyte or product of the analyte and a surface-immobilized intermediary. The resultant magnitude of potential or current arising from the redox reaction, which reflects the concentration of analyte in the physiological medium, is then routed to an external integrated circuit, module, or self-contained device for interpretation. In order to facilitate electrical interface between the skin-penetrating regions of the microneedle and a suitable location where the redox signal can be probed, conductive traces are spatially defined from the sensing region located on the microneedle surface to a pad located on the extremities of the substrate upon which the microneedles are secured. However, current chip-scale packaging techniques such as wire-bonding mandate that electrical leads be soldered on the same surface in which the microneedles are located; this can interfere with the insertion of the said microneedles due to increased standoff. On the other hand, flip-chip techniques mandate that the substrate be ‘flipped’ to facilitate electrical interface, which thereby serves to orient the microneedle structure(s) away from the intended application site and into the interior of the package itself. In order to maintain compatibility with existent packaging methods, the fabrication of said microneedle devices mandates that a spatially-defined conductive region be realized between the sensing surface located on the microneedle structure and the posterior surface of the substrate that the said microneedle is located. In accordance with current practice, this has proven difficult to remedy as the spatial definition of a suitable conduit providing electrical communication between two opposing sides of the substrate required modifications to the fabrication methodology.
Prior art solutions have been concerned with patterned, planar conductive traces routing the electrical signal from the microneedle surface to a spatially defined region (pad) suitable for probing/wire-bonding to facilitate implementation in an integrated circuit-style package. The said pad is located on the same surface as the microneedle structure, which, when attached to an external circuit with bonding wire, will cause increased standoff and prevent the microneedle structure from fully inserting into the viable epidermis or dermis. The trace is not routed through the substrate supporting said microneedle(s) and occupies the same surface as the microneedle.
U.S. Pat. No. 6,551,849 for a Method For Fabricating Arrays Of Micro-Needles discloses an array of micro-needles is created by forming an array pattern on the upper surface of a silicon wafer and etching through openings in the pattern to define micro-needle sized cavities having a desired depth. The mold thus formed may be filled with electrically conductive material, after which a desired fraction of the silicon wafer bulk is removed from the bottom-up by etching, to expose an array of projecting micro-needles. The mold may instead be filled with a flexible material to form a substrate useful in gene cell probing. An array of hollow micro-needles may be formed by coating the lower wafer surface with SiN, and etching through pattern openings in the upper surface down to the SiN layer, and then conformally coating the upper surface with thermal silicon dioxide. The SiN layer is then stripped away and a desired fraction of the bulk of the wafer removed from the bottom-up to expose an array of projecting hollow micro-needles.
U.S. Patent Publication Number 20140303471 for Non-Invasive Segmentable Three-Dimensional Microelectrode Array Patch For Neurophysiological Diagnostics And Therapeutic Stimulation discloses implementations disclosed herein provide for a microneedle electrode system comprising a microneedle electrode patch connected to external electronics. The microneedle electrode patch comprises a first flexible substrate having a plurality of conductive pads disposed thereon, a plurality of three-dimensional, individually addressable microneedle electrode arrays where each array has a plurality of microneedles extending from an upper surface thereof and a lower surface adapted to contact a corresponding one of the plurality of conductive pads disposed on the first substrate, and a second flexible substrate having a plurality of openings defined therein dimensioned to accommodate at least a portion of the upper surface of the microneedle electrode array from which the microneedles extend. Each of the conductive pads is disposed in electrical communication with a corresponding one of the plurality of microneedle electrode arrays and the first and second substrate are bonded together such that each one of the plurality of microneedle electrode arrays extends through a corresponding one of the plurality of openings defined in the second substrate.
U.S. Pat. No. 8,308,960 for Methods for Making Microneedles and Applications Thereof discloses a method of making vertically protruding elements on a substrate, said elements having a tip comprising at least one inclined surface and an elongated body portion extending between said substrate and said tip. The method comprises an anisotropic, crystal plane dependent etch forming said inclined surface(s); and an anisotropic, non crystal plane dependent etch forming said elongated body portion; combined with suitable patterning processes defining said protruding elements to have a predetermined base geometry.
U.S. Pat. No. 8,637,351 for Methods for Making Microneedles and Applications Thereof discloses a method of making vertically protruding elements on a substrate, said elements having a tip comprising at least one inclined surface and an elongated body portion extending between said substrate and said tip. The method comprises an anisotropic, crystal plane dependent etch forming said inclined surface(s); and an anisotropic, non crystal plane dependent etch forming said elongated body portion; combined with suitable patterning processes defining said protruding elements to have a predetermined base geometry.
The current solution teaches of a means to implement a spatially-defined, conductive conduit between the sensing surface of a microneedle (or array of microneedles) located on a planar substrate and the opposing surface of said substrate. In doing so, the need to make ohmic contact with the microneedle-containing surface of the substrate is mitigated, which enables unobstructed insertion of the said microneedle (or array of microneedles) into the viable epidermis or dermis.
The technology described herein involves a method for circumscribing an insulating barrier region around a singular conductive microneedle structure or plurality of conductive microneedle structures adhered to a fixed substrate for the purpose of spatially defining a conduit for the routing of an electrical signal from the surface of said microneedle or microneedles to the posterior surface of said substrate.
One aspect of the present invention is a microneedle-based electrochemical biosensors structure. The structure comprises a substrate, a microneedle biosensor, a primary electrically conductive element, a secondary electrically conductive element and an electrically insulative annular barrier. The substrate is composed of an electrically conducting material, the substrate comprising an anterior surface and a posterior surface. The microneedle biosensor has a length ranging from 20 microns to 2000 microns. The microneedle biosensor comprises a penetrating end and a posterior end. The microneedle biosensor protrudes from the anterior surface of the substrate and having a portion within the substrate. The primary electrically conductive element is located on the penetrating end of the microneedle biosensor. The secondary electrically conductive element is located on the posterior end of the microneedle biosensor. The electrically insulative annular barrier surrounds the portion of microneedle biosensor that is embedded in the substrate to electrically isolate the microneedle biosensor from the substrate.
Another aspect of the present invention is a microneedle-based electrochemical biosensors structure. The structure comprises a substrate, a plurality of microneedle biosensors, a primary electrically conductive element, a secondary electrically conductive element and an electrically insulative annular barrier. The substrate is composed of an electrically conducting material, the substrate comprising an anterior surface and a posterior surface. Each of the plurality of microneedle biosensors has a length ranging from 20 microns to 2000 microns. Each microneedle biosensor comprises a penetrating end and a posterior end, each microneedle biosensor protruding from the anterior surface of the substrate and having a portion within the substrate. The primary electrically conductive element is located on the penetrating end of each microneedle biosensor. The secondary electrically conductive element is located on the posterior end of each microneedle biosensor. The electrically insulative annular barrier surrounds the portion of each microneedle biosensor that is embedded in the substrate to electrically isolate the microneedle biosensor from the substrate.
Yet another aspect of the present invention is a microneedle-based electrochemical biosensors structure with a printed circuit board (PCB). The structure comprises a PCB, a substrate, a plurality of microneedle biosensors, a primary electrically conductive element, a secondary electrically conductive element, an electrically insulative annular barrier and a plurality of phase-change conductive interconnects. The PCB comprises a pad, at least one via and a plurality of traces. The substrate is composed of an electrically conducting material, the substrate comprising an anterior surface and a posterior surface. Each of the plurality of microneedle biosensors has a length ranging from 20 microns to 2000 microns. Each microneedle biosensor comprises a penetrating end and a posterior end, each microneedle biosensor protruding from the anterior surface of the substrate and having a portion within the substrate. The primary electrically conductive element is located on the penetrating end of each microneedle biosensor. The secondary electrically conductive element is located on the posterior end of each microneedle biosensor. The electrically insulative annular barrier surrounds the portion of each microneedle biosensor that is embedded in the substrate to electrically isolate the microneedle biosensor from the substrate. The phase-change conductive interconnect is positioned between the pad of the printed circuit board and the secondary electrically conductive element.
Yet another aspect of the present invention is a microneedle-based electrochemical biosensors structure with a printed circuit board (PCB). The structure comprises a PCB, a substrate, a microneedle biosensor, a primary electrically conductive element, a secondary electrically conductive element, an electrically insulative annular barrier and a plurality of phase-change conductive interconnects. The PCB comprises a pad, at least one via and a plurality of traces. The substrate is composed of an electrically conducting material, the substrate comprising an anterior surface and a posterior surface. Each of the plurality of microneedle biosensors has a length ranging from 20 microns to 2000 microns. Each microneedle biosensor comprises a penetrating end and a posterior end, each microneedle biosensor protruding from the anterior surface of the substrate and having a portion within the substrate. The primary electrically conductive element is located on the penetrating end of each microneedle biosensor. The secondary electrically conductive element is located on the posterior end of each microneedle biosensor. The electrically insulative annular barrier surrounds a portion of the length of each microneedle biosensor to electrically isolate the microneedle biosensor from the substrate. Each of the phase-change conductive interconnects is positioned between the pad of the printed circuit board and the secondary electrically conductive element of each microneedle biosensor.
Yet another aspect of the invention is the jetting of solder balls, spheres, or solder bumps onto the secondary conductive element on located on the posterior end of each microneedle biosensor to facilitate solder reflow with pads located on the IC, IC package, chip carrier, or PCB. Said solder balls, spheres, or solder bumps may be simultaneously jetted onto the secondary conductive element and heated by means of a reflow laser to facilitate adhesion of said solder balls, spheres, or solder bumps onto the underlying secondary conductive element. Optionally, said process can be implemented on a wafer scale or by means of wafer-level solder balling to accelerate the rate at which said jetting occurs. In such a process, solder balls, spheres, or solder bumps are attached, simultaneously, to all the secondary conductive elements located on the posterior ends of each microneedle biosensor on a wafer substrate in a highly parallelized fashion.
Yet another aspect of the invention is the attachment of an electrically-conductive epoxy to at least one of a secondary conductive element on located on the posterior end of each microneedle biosensor and a pad located on an IC, IC package, chip carrier, or PCB. Optionally, heat can be employed to reflow the electrically-conductive epoxy. Optionally, the electrically-conductive epoxy can cure following UV exposure. Optionally, the electrically-conductive epoxy can cure following remaining at ambient conditions for a defined period of time.
Yet another aspect of the invention is the incorporation of a conducting metallic pillar into the solder ball, sphere, or bump to increase the standoff between the secondary electrically conductive element located on the posterior end of each microneedle biosensor and the underlying pad located on the surface of an IC, IC package, chip carrier, or PCB.
Yet another aspect of the invention is the selection of the secondary conductive element on located on the posterior end of each microneedle biosensor to facilitate stud bumping or the attachment of solder balls. Said conductive element can be selected from, for example, gold, nickel, aluminum, and palladium or be comprised of a bi- or tri-metallic alloy of any permutation of the same.
Yet another aspect of the invention is the selection of the pad material located on the IC, IC package, chip carrier, or PCB. The selection of the material is to facilitate stud bumping or the attachment of solder balls. Said pad material can be selected from, for example, gold, nickel, aluminum, and palladium or be comprised of a bi- or tri-metallic alloy of any permutation of the same.
Having briefly described the present invention, the above and further objects, features and advantages thereof will be recognized by those skilled in the pertinent art from the following detailed description of the invention when taken in conjunction with the accompanying drawings.
The technology disclosed herein addresses the above challenge via the implementation of fully-insulating barriers that circumscribe and thereby electrically isolate the microneedle (or plurality of microneedles) from other locations on the substrate. In this manner, an electrical signal can be routed from a spatially-defined electrically-conductive region located on the tip of the microneedle (or plurality of microneedles) to the posterior surface of the substrate to facilitate probing and device-level packaging while leaving the surface containing the microneedle(s) exposed to enable skin penetration and subsequent sensing operation. An electrically-conductive substrate (i.e. semiconductor wafer, polymer wafer, glass wafer, ceramic wafer, or metal wafer) containing microneedles on the anterior surface (each microneedle featuring a primary electrically-conductive element (i.e. metal, semiconductor, conducting polymer) in ohmic contact with the conductive substrate) and a secondary electrically-conductive element (i.e. metal, semiconductor, conducting polymer) on the posterior surface undergoes an etching process whereby substrate material in an annular region circumscribing one or more conductive microneedles is removed. The trench created in this process, which must be less than the thickness of the substrate, is filled with an insulating material (growth of a native oxide or deposition of an electrically-insulating compound). The substrate is then flipped to expose the opposing surface and another trench (having identical geometric features to the aforementioned trench) is etched to a depth sufficient to access the opposing filled trench. This trench is subsequently filled with an insulating material (growth of a native oxide or deposition of an electrically-insulating compound). In this fashion, an isolated, electrically-conducting region extending from the primary electrical contact (located on or within the microneedle structure) to the secondary electrical contact is realized. The secondary electrically-conductive element is either probed directly, bonded to solder bumps and exposed to solder reflow to attach to pads populating a printed circuit board (PCB), or bonded to solder bumps located within an integrated circuit package. The IC package can be probed directly, placed in a socket, or soldered onto a printed circuit board to facilitate electrochemical analysis (control of the redox reaction and readout of the signal). This approach is in direct analogy to conductive through-silicon vias implemented in silicon-based semiconductor substrates, which are widely used in 3-dimensional semiconductor manufacturing and wafer-level packaging. The differentiating feature in the current innovation resides in the approach of ‘filling’ the via with insulating material and circumscribing an enclosed region with said via to facilitate full electrical isolation from other portions of the substrate not located within the enclosed region.
The structure preferably includes a substrate, a microneedle biosensor, a primary electrically-conductive element, a secondary electrically-conductive element, and an electrically-insulative annular barrier. The substrate is fabricated from an intrinsically conducting or semiconducting material (i.e. doped semiconductor wafer, conducting polymer wafer, glass wafer, ceramic wafer, or metal wafer). The substrate features anterior and posterior surfaces. The microneedle biosensor is a defined protrusion from the anterior surface of the substrate possessing vertical extent of between 20 and 2000 μm and designed to penetrate the stratum corneum or other biological tissue to access a viable physiological fluid (such as blood, plasma, serum, or interstitial fluid). The primary electrically-conductive element is a defined conductive region located on the surface of said microneedle structure, intended to react, either directly or indirectly, with a chemical analyte in the physiological medium. The secondary electrically-conductive element is a defined conductive region located on the posterior surface of said substrate, intended to enable ohmic contact with a electrical probing mechanism or bonding/soldering to an integrated circuit package or printed circuit board. The electrically-insulative annular barrier is an annular barrier, defined via an etching, milling, machining, ablative, or otherwise subtractive processes, filled with an electrically insulating material to spatially define a region of conductivity within the annulus and provide isolation with the substrate located to the exterior of said annulus. The electrically insulating material can be filled by means of the oxidative growth of a native, non-conducting oxide, nitride, or other alloy or the additive deposition of the same.
The method for manufacturing the structure includes etching, milling, machining, or ablating of an anterior trench in which an etching process is used on the anterior surface of a conductive substrate to remove material in a defined patterned region, thereby defining an anterior trench. The method also includes implementation of an insulating material in anterior trench in which an insulating layer is grown or deposition of an insulating material in said anterior trench. The method also includes etching, milling, machining, or ablating of the posterior trench in which one of the etching, milling, machining, or ablating process is used on the posterior surface of said conductive substrate to remove material in a defined patterned region, thereby defining a posterior trench. Substrate material is etched, milled, machined, or ablated to a depth that is equal to or greater than the difference between the substrate thickness and the depth of the anterior trench, but less than the overall thickness of the substrate. The method also includes implementation of an insulating material in posterior trench in which an insulating layer is grown or deposition of an insulating material in said posterior trench.
One embodiment is a microneedle-based electrochemical biosensors structure 1 with a printed circuit board (PCB) 85. The structure 1 comprises a PCB 85, a substrate 15, a microneedle biosensor 10, a primary electrically conductive element 5, a secondary electrically conductive element 6, an electrically insulative annular barrier 20 and a plurality of phase-change conductive interconnects. The phase-change conductive interconnect is preferably one of a solder ball 80 and a conductive epoxy. The PCB 85 comprises a pad 81, at least one via 83 and a plurality of traces 82. The substrate 15 is preferably composed of an electrically conducting material. The substrate preferably comprises an anterior surface 16 and a posterior surface 17. Each of the plurality of microneedle biosensors 10 has a length ranging from 20 microns to 2000 microns. Each microneedle biosensor 10 comprises a penetrating end and a posterior end. Each microneedle biosensor 10 protrudes from the anterior surface 16 of the substrate 15 and has a portion within the substrate 15. The primary electrically conductive element 5 is located on the penetrating end of each microneedle biosensor 10. The secondary electrically conductive element 6 is located on the posterior end of each microneedle biosensor 10. The electrically insulative annular barrier 20 surrounds the length of each microneedle biosensor 10 to electrically isolate the microneedle biosensor 10 from the substrate 15. Each of the phase-change conductive interconnects 80 is positioned between the pad 81 of the PCB 85 and the secondary electrically conductive element 6 of each microneedle biosensor 10.
The secondary electrically conductive element 6 is preferably composed of a metal, a doped region of semiconductor, or a conducting polymer.
Each microneedle biosensor 10 is preferably configured to penetrate a stratum corneum of a mammal.
The biological interface is preferably a stratum corneum.
The substrate 15 is preferably composed of a semiconductor wafer, a rigid polymer, a flexible polymer, a glass material, a ceramic material, or a metal material.
McCanna et al., U.S. patent application Ser. No. 14/843,926, filed on Sep. 2, 2015, for a Miniaturized Sub-Nanoampere Sensitivity Low-Noise Potentiostat System is hereby incorporated by reference in its entirety.
Windmiller et al., U.S. patent application Ser. No. 14/955,850, filed on Dec. 1, 2015, for a Method And Apparatus For Determining Body Fluid Loss is hereby incorporated by reference in its entirety.
Windmiller, U.S. patent application Ser. No. 15/177,289, filed on Jun. 8, 2016, for a Methods And Apparatus For Interfacing A Microneedle-Based Electrochemical Biosensor With An External Wireless Readout Device is hereby incorporated by reference in its entirety.
Wang et al., U.S. Patent Publication Number 20140336487 for a Microneedle Arrays For Biosensing And Drug Delivery is hereby incorporated by reference in its entirety.
Windmiller, U.S. patent application Ser. No. 15/590,105 for a Tissue-Penetrating Electrochemical Sensor Featuring A Co Electrodeposited Thin Film Comprised Of A Polymer And Bio-Recognition Element is hereby incorporated by reference in its entirety.
PCT Application Number PCT/US17/55314 for an Electro-Deposited Conducting Polymers For The Realization Of Solid-State Reference Electrodes For Use In Intracutaneous And Subcutaneous Analyte-selective Sensors is hereby incorporated by reference in its entirety.
From the foregoing it is believed that those skilled in the pertinent art will recognize the meritorious advancement of this invention and will readily understand that while the present invention has been described in association with a preferred embodiment thereof, and other embodiments illustrated in the accompanying drawings, numerous changes modification and substitutions of equivalents may be made therein without departing from the spirit and scope of this invention which is intended to be unlimited by the foregoing except as may appear in the following appended claim. Therefore, the embodiments of the invention in which an exclusive property or privilege is claimed are defined in the following appended claims.
The present Application claims priority to U.S. Provisional Patent Application No. 62/470,204 filed on Mar. 11, 2017, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4305401 | Reissmueller et al. | Dec 1981 | A |
4323996 | Ganter | Apr 1982 | A |
4407295 | Steuer et al. | Oct 1983 | A |
4450842 | Zick et al. | May 1984 | A |
4908117 | Kinlen et al. | Mar 1990 | A |
4969468 | Byers et al. | Nov 1990 | A |
5035711 | Aoki et al. | Jul 1991 | A |
5131390 | Sakaguchi et al. | Jul 1992 | A |
5279543 | Glikfeld et al. | Jan 1994 | A |
5286364 | Yacynych et al. | Feb 1994 | A |
5540828 | Yacynych | Jul 1996 | A |
5730714 | Guy et al. | Mar 1998 | A |
5766132 | Yasukawa et al. | Jun 1998 | A |
5832410 | Lin et al. | Nov 1998 | A |
5869078 | Baudino | Feb 1999 | A |
5953306 | Yi | Sep 1999 | A |
6036055 | Mogadam et al. | Mar 2000 | A |
6091975 | Daddona et al. | Jul 2000 | A |
6132449 | Lum et al. | Oct 2000 | A |
6132499 | Wong et al. | Oct 2000 | A |
6132755 | Eicher et al. | Oct 2000 | A |
6139718 | Kurnik et al. | Oct 2000 | A |
6269053 | Kawata et al. | Jul 2001 | B1 |
6284126 | Kurnik et al. | Sep 2001 | B1 |
6364890 | Lum et al. | Apr 2002 | B1 |
6413396 | Yang et al. | Jul 2002 | B1 |
6465091 | Ou-yang | Oct 2002 | B1 |
6471903 | Sherman et al. | Oct 2002 | B2 |
6527762 | Santini, Jr. et al. | Mar 2003 | B1 |
6551849 | Kenney | Apr 2003 | B1 |
6587705 | Kim et al. | Jul 2003 | B1 |
6599408 | Chan et al. | Jul 2003 | B1 |
6603987 | Whitson | Aug 2003 | B2 |
6611707 | Prausnitz et al. | Aug 2003 | B1 |
6793789 | Choi et al. | Sep 2004 | B2 |
6801041 | Karinka et al. | Oct 2004 | B2 |
6814845 | Wilson et al. | Nov 2004 | B2 |
6862466 | Ackerman | Mar 2005 | B2 |
6908453 | Fleming et al. | Jun 2005 | B2 |
7081195 | Simpson et al. | Jul 2006 | B2 |
7097776 | Raju | Aug 2006 | B2 |
7132054 | Kravitz et al. | Nov 2006 | B1 |
7183068 | Burson et al. | Feb 2007 | B2 |
7262068 | Roy et al. | Aug 2007 | B2 |
7343188 | Sohrab | Mar 2008 | B2 |
7344499 | Prausnitz et al. | Mar 2008 | B1 |
7366556 | Brister et al. | Apr 2008 | B2 |
7415299 | Zimmermann et al. | Aug 2008 | B2 |
7429333 | Chiou et al. | Sep 2008 | B2 |
7456112 | Lee | Nov 2008 | B2 |
7471972 | Rhodes et al. | Dec 2008 | B2 |
7473244 | Frazier et al. | Jan 2009 | B2 |
7493232 | Surina | Feb 2009 | B1 |
7534330 | Yu et al. | May 2009 | B2 |
7583990 | Goode, Jr. | Sep 2009 | B2 |
7599726 | Goode, Jr. | Oct 2009 | B2 |
7613491 | Boock | Nov 2009 | B2 |
7645263 | Angel et al. | Jan 2010 | B2 |
7715893 | Kamath et al. | May 2010 | B2 |
7725148 | Shah et al. | May 2010 | B2 |
7768408 | Reggiardo et al. | Aug 2010 | B2 |
7778680 | Goode, Jr. | Aug 2010 | B2 |
7797028 | Goode, Jr. | Sep 2010 | B2 |
7811231 | Jin et al. | Oct 2010 | B2 |
7837654 | Shumate et al. | Nov 2010 | B2 |
7885697 | Brister et al. | Feb 2011 | B2 |
7905833 | Brister et al. | Mar 2011 | B2 |
7917186 | Kamath et al. | Mar 2011 | B2 |
7949382 | Jina | May 2011 | B2 |
7959569 | Goode et al. | Jun 2011 | B2 |
8005526 | Martin et al. | Aug 2011 | B2 |
8010174 | Goode, Jr. | Aug 2011 | B2 |
8022292 | Arianpour et al. | Sep 2011 | B2 |
8064977 | Boock et al. | Nov 2011 | B2 |
8088321 | Ferguson et al. | Jan 2012 | B2 |
8094009 | Allen et al. | Jan 2012 | B2 |
8108023 | Mir et al. | Jan 2012 | B2 |
8110079 | Gooding et al. | Feb 2012 | B2 |
8125331 | Allen et al. | Feb 2012 | B2 |
8130095 | Allen et al. | Mar 2012 | B2 |
8160665 | Mischler et al. | Apr 2012 | B2 |
8160671 | Kamath et al. | Apr 2012 | B2 |
8160834 | Liang et al. | Apr 2012 | B2 |
8162901 | Gonnelli et al. | Apr 2012 | B2 |
RE43399 | Simpson et al. | May 2012 | E |
8216138 | McGarraugh | Jul 2012 | B1 |
8236368 | Jung et al. | Aug 2012 | B2 |
8249684 | Kamath et al. | Aug 2012 | B2 |
8257324 | Prausnitz et al. | Sep 2012 | B2 |
8280475 | Brister et al. | Oct 2012 | B2 |
8280476 | Jina | Oct 2012 | B2 |
8284046 | Allen et al. | Oct 2012 | B2 |
8287453 | Li et al. | Oct 2012 | B2 |
8308960 | Kalvesten et al. | Nov 2012 | B2 |
8346335 | Harper et al. | Jan 2013 | B2 |
8376945 | Hayter et al. | Feb 2013 | B2 |
8386004 | Kamath et al. | Feb 2013 | B2 |
8423114 | Simpson et al. | Apr 2013 | B2 |
8428678 | Kamath et al. | Apr 2013 | B2 |
8452369 | Huys et al. | May 2013 | B2 |
8463350 | Kamath et al. | Jun 2013 | B2 |
8483793 | Simpson et al. | Jul 2013 | B2 |
8506529 | Yang | Aug 2013 | B1 |
8548553 | Kamath et al. | Oct 2013 | B2 |
8565848 | Brister et al. | Oct 2013 | B2 |
8574165 | Marsh | Nov 2013 | B2 |
8617069 | Bernstein et al. | Dec 2013 | B2 |
RE44695 | Simpson et al. | Jan 2014 | E |
8626257 | Li et al. | Jan 2014 | B2 |
8637351 | Kalvesten et al. | Jan 2014 | B2 |
8660628 | Wang et al. | Feb 2014 | B2 |
8700114 | Gottlieb et al. | Apr 2014 | B2 |
8708966 | Allen et al. | Apr 2014 | B2 |
8798799 | Deo et al. | Aug 2014 | B2 |
8815070 | Wang et al. | Aug 2014 | B2 |
8870763 | Yang et al. | Oct 2014 | B2 |
8882665 | Yang et al. | Nov 2014 | B2 |
9008743 | Hayter et al. | Apr 2015 | B2 |
9008745 | Pushpala et al. | Apr 2015 | B2 |
9055901 | Brister et al. | Jun 2015 | B2 |
9125625 | Wang et al. | Sep 2015 | B2 |
9182368 | Pushpala et al. | Nov 2015 | B2 |
9234872 | Homyk et al. | Jan 2016 | B2 |
9248273 | Guvanasen et al. | Feb 2016 | B2 |
9332934 | Hayter et al. | May 2016 | B2 |
9336423 | Goodnow et al. | May 2016 | B2 |
9357951 | Simpson | Jun 2016 | B2 |
9386954 | Saini et al. | Jul 2016 | B2 |
9387000 | Corrie et al. | Jul 2016 | B2 |
9414778 | Mao et al. | Aug 2016 | B2 |
9420965 | Brauker et al. | Aug 2016 | B2 |
9532741 | Brauker et al. | Jan 2017 | B2 |
9551698 | Huys et al. | Jan 2017 | B2 |
9662056 | Budiman et al. | May 2017 | B2 |
9737247 | Wang et al. | Aug 2017 | B2 |
9743870 | Wang et al. | Aug 2017 | B2 |
9743871 | Simpson et al. | Aug 2017 | B2 |
9757061 | Shults et al. | Sep 2017 | B2 |
9770211 | Hayter et al. | Sep 2017 | B2 |
9804114 | Rhodes et al. | Oct 2017 | B2 |
9933387 | McCanna et al. | Apr 2018 | B1 |
9958409 | Gerber et al. | May 2018 | B2 |
10022076 | Hoss et al. | Jul 2018 | B2 |
10039480 | Brauker et al. | Aug 2018 | B2 |
10046114 | Biederman et al. | Aug 2018 | B1 |
10052055 | Li et al. | Aug 2018 | B2 |
10092207 | Windmiller | Oct 2018 | B1 |
10136846 | Wang et al. | Nov 2018 | B2 |
10173042 | Pushpala et al. | Jan 2019 | B2 |
10182748 | Catt et al. | Jan 2019 | B2 |
10188333 | Kamath et al. | Jan 2019 | B2 |
10228341 | Katsuki et al. | Mar 2019 | B2 |
10299712 | Brister et al. | May 2019 | B2 |
10327678 | Gottlieb et al. | Jun 2019 | B2 |
10492708 | Windmiller | Dec 2019 | B1 |
D875254 | Cooke et al. | Feb 2020 | S |
10549080 | Pushpala et al. | Feb 2020 | B2 |
10610103 | Brister et al. | Apr 2020 | B2 |
10709332 | Brister et al. | Jul 2020 | B2 |
10743800 | Larvenz et al. | Aug 2020 | B2 |
10780222 | Ward et al. | Sep 2020 | B2 |
10820860 | Pushpala et al. | Nov 2020 | B2 |
10881334 | Facchinetti et al. | Jan 2021 | B2 |
10932700 | Simpson et al. | Mar 2021 | B2 |
10983083 | Harding et al. | Apr 2021 | B2 |
11020026 | Boock et al. | Jun 2021 | B2 |
11035872 | Boutelle et al. | Jun 2021 | B2 |
11045142 | Windmiller et al. | Jun 2021 | B1 |
11051724 | Pace et al. | Jul 2021 | B2 |
11123532 | Pushpala et al. | Sep 2021 | B2 |
11179068 | Pace et al. | Nov 2021 | B2 |
11197985 | Pushpala et al. | Dec 2021 | B2 |
11272866 | Pushpala et al. | Mar 2022 | B2 |
11272885 | Pushpala et al. | Mar 2022 | B2 |
11291390 | Pushpala et al. | Apr 2022 | B2 |
11331022 | Halac et al. | May 2022 | B2 |
11359300 | Beer et al. | Jun 2022 | B1 |
11406818 | Windmiller | Aug 2022 | B2 |
11478194 | Windmiller et al. | Oct 2022 | B2 |
11596332 | Shults et al. | Mar 2023 | B2 |
11654270 | Mansfield, III et al. | May 2023 | B2 |
D988160 | Morelock | Jun 2023 | S |
11672965 | Mansfield, III et al. | Jun 2023 | B2 |
D996999 | Morelock | Aug 2023 | S |
D1012744 | Morelock | Jan 2024 | S |
11857344 | Windmiller et al. | Jan 2024 | B2 |
11872055 | Tangney et al. | Jan 2024 | B2 |
D1013544 | Morelock | Feb 2024 | S |
11904127 | Mansfield, III et al. | Feb 2024 | B2 |
11963796 | Windmiller et al. | Apr 2024 | B1 |
20020004640 | Conn et al. | Jan 2002 | A1 |
20020020688 | Sherman et al. | Feb 2002 | A1 |
20020055704 | Scott et al. | May 2002 | A1 |
20020072784 | Norman, Jr. et al. | Jun 2002 | A1 |
20020105080 | Speakman | Aug 2002 | A1 |
20020187556 | Shartle | Dec 2002 | A1 |
20030068666 | Zweig | Apr 2003 | A1 |
20030088166 | Say | May 2003 | A1 |
20030095582 | Ackley | May 2003 | A1 |
20030100040 | Bonnecaze et al. | May 2003 | A1 |
20030104119 | Wilson et al. | Jun 2003 | A1 |
20030135158 | Gonnelli | Jul 2003 | A1 |
20030208167 | Prausnitz et al. | Nov 2003 | A1 |
20030225360 | Eppstein et al. | Dec 2003 | A1 |
20030235817 | Bartkowiak et al. | Dec 2003 | A1 |
20040065158 | Schrepfer et al. | Apr 2004 | A1 |
20040082875 | Donoghue et al. | Apr 2004 | A1 |
20040220625 | Silvestri et al. | Nov 2004 | A1 |
20050036020 | Li et al. | Feb 2005 | A1 |
20050101841 | Kaylor et al. | May 2005 | A9 |
20050137536 | Gonnelli | Jun 2005 | A1 |
20050209565 | Yuzhakov et al. | Sep 2005 | A1 |
20050267440 | Herman et al. | Dec 2005 | A1 |
20050272989 | Shah et al. | Dec 2005 | A1 |
20060015061 | Kuo et al. | Jan 2006 | A1 |
20060016700 | Brister et al. | Jan 2006 | A1 |
20060173259 | Flaherty et al. | Aug 2006 | A1 |
20060264716 | Zander | Nov 2006 | A1 |
20060281121 | Unger et al. | Dec 2006 | A1 |
20070078445 | Malloy | Apr 2007 | A1 |
20070169533 | Shah et al. | Jul 2007 | A1 |
20070170054 | Wilsey | Jul 2007 | A2 |
20070213044 | Steingart et al. | Sep 2007 | A1 |
20070282246 | Henley | Dec 2007 | A1 |
20080009800 | Nickel | Jan 2008 | A1 |
20080009801 | Nickel | Jan 2008 | A1 |
20080027369 | Carter et al. | Jan 2008 | A1 |
20080033269 | Zhang | Feb 2008 | A1 |
20080097280 | Martin et al. | Apr 2008 | A1 |
20080097352 | Beck et al. | Apr 2008 | A1 |
20080119707 | Stafford | May 2008 | A1 |
20080154107 | Jina | Jun 2008 | A1 |
20080156661 | Cooper et al. | Jul 2008 | A1 |
20080213461 | Gill et al. | Sep 2008 | A1 |
20080221408 | Hoarau et al. | Sep 2008 | A1 |
20080234562 | Jina | Sep 2008 | A1 |
20080255434 | Hayter et al. | Oct 2008 | A1 |
20080275327 | Faarbaek et al. | Nov 2008 | A1 |
20090057148 | Wieder et al. | Mar 2009 | A1 |
20090066348 | Shin et al. | Mar 2009 | A1 |
20090069651 | Zimmermann et al. | Mar 2009 | A1 |
20090069697 | Frazier et al. | Mar 2009 | A1 |
20090084678 | Joshi et al. | Apr 2009 | A1 |
20090088652 | Tremblay | Apr 2009 | A1 |
20090090623 | Chuang et al. | Apr 2009 | A1 |
20090099427 | Jina et al. | Apr 2009 | A1 |
20090101498 | Papadimitrakopoulos et al. | Apr 2009 | A1 |
20090118672 | Gonnelli et al. | May 2009 | A1 |
20090131778 | Jina et al. | May 2009 | A1 |
20090143761 | Cantor et al. | Jun 2009 | A1 |
20090152598 | Baek et al. | Jun 2009 | A1 |
20090191616 | Lu et al. | Jul 2009 | A1 |
20090198118 | Hayter et al. | Aug 2009 | A1 |
20090218239 | Gooding et al. | Sep 2009 | A1 |
20090259118 | Feldman et al. | Oct 2009 | A1 |
20090294306 | Feldman et al. | Dec 2009 | A1 |
20100006451 | Gordon et al. | Jan 2010 | A1 |
20100021637 | Revol et al. | Jan 2010 | A1 |
20100022416 | Flemming et al. | Jan 2010 | A1 |
20100025238 | Gottlieb et al. | Feb 2010 | A1 |
20100030045 | Gottlieb et al. | Feb 2010 | A1 |
20100049021 | Jina et al. | Feb 2010 | A1 |
20100052892 | Allen et al. | Mar 2010 | A1 |
20100052897 | Allen et al. | Mar 2010 | A1 |
20100052898 | Allen et al. | Mar 2010 | A1 |
20100052915 | Allen et al. | Mar 2010 | A1 |
20100056873 | Allen et al. | Mar 2010 | A1 |
20100137779 | Seitz | Jun 2010 | A1 |
20100200538 | Petisce et al. | Aug 2010 | A1 |
20100279377 | Shah et al. | Nov 2010 | A1 |
20100286803 | Tillotson | Nov 2010 | A1 |
20110027127 | Simpson et al. | Feb 2011 | A1 |
20110077490 | Simpson et al. | Mar 2011 | A1 |
20110105871 | Zimmermann et al. | May 2011 | A1 |
20110140703 | Chiao et al. | Jun 2011 | A1 |
20110210017 | Lai et al. | Sep 2011 | A1 |
20110224515 | Mir et al. | Sep 2011 | A1 |
20110230736 | Tepper et al. | Sep 2011 | A1 |
20110237925 | Yue et al. | Sep 2011 | A1 |
20110247934 | Wang et al. | Oct 2011 | A1 |
20110275918 | Yamashita et al. | Nov 2011 | A1 |
20110306853 | Black et al. | Dec 2011 | A1 |
20110319787 | Lamoise et al. | Dec 2011 | A1 |
20120018302 | Shiraki et al. | Jan 2012 | A1 |
20120037515 | Solanki | Feb 2012 | A1 |
20120067734 | Wang et al. | Mar 2012 | A1 |
20120078071 | Bohm et al. | Mar 2012 | A1 |
20120123232 | Najarian et al. | May 2012 | A1 |
20120172692 | Tamada et al. | Jul 2012 | A1 |
20120209244 | Gray | Aug 2012 | A1 |
20120277629 | Bernstein et al. | Nov 2012 | A1 |
20120323097 | Chowdhury | Dec 2012 | A9 |
20130053660 | Shieh | Feb 2013 | A1 |
20130065257 | Wang et al. | Mar 2013 | A1 |
20130135158 | Faraone et al. | May 2013 | A1 |
20130144131 | Wang et al. | Jun 2013 | A1 |
20130158376 | Hayter et al. | Jun 2013 | A1 |
20130225956 | Huang et al. | Aug 2013 | A1 |
20130281808 | Shieh | Oct 2013 | A1 |
20130338746 | Guvanasen et al. | Dec 2013 | A1 |
20130345597 | Hagino et al. | Dec 2013 | A1 |
20140135679 | Mann et al. | May 2014 | A1 |
20140259652 | Pushpala et al. | Sep 2014 | A1 |
20140275897 | Pushpala et al. | Sep 2014 | A1 |
20140275899 | Gottlieb et al. | Sep 2014 | A1 |
20140275907 | Feldman et al. | Sep 2014 | A1 |
20140303471 | Rajaraman et al. | Oct 2014 | A1 |
20140336487 | Wang et al. | Nov 2014 | A1 |
20140378804 | Kalvesten | Dec 2014 | A1 |
20150073238 | Matsumoto et al. | Mar 2015 | A1 |
20150126834 | Wang et al. | May 2015 | A1 |
20150208970 | Huang | Jul 2015 | A1 |
20150243851 | Lee et al. | Aug 2015 | A1 |
20150276758 | Addisu | Oct 2015 | A1 |
20150313527 | Renlund | Nov 2015 | A1 |
20160029937 | Sia et al. | Feb 2016 | A1 |
20160058342 | Maiz-Aquinaga et al. | Mar 2016 | A1 |
20160095541 | Wang et al. | Apr 2016 | A1 |
20160095547 | Wang et al. | Apr 2016 | A1 |
20160139069 | Wang | May 2016 | A1 |
20160157764 | Di Palma et al. | Jun 2016 | A1 |
20160158514 | Stoeber | Jun 2016 | A1 |
20160166184 | Teng et al. | Jun 2016 | A1 |
20160258945 | Malima et al. | Sep 2016 | A1 |
20160270704 | DeTurk | Sep 2016 | A1 |
20160296149 | Polsky et al. | Oct 2016 | A1 |
20160302687 | Lee et al. | Oct 2016 | A1 |
20160370377 | Ahmad | Dec 2016 | A1 |
20170003766 | Budiman | Jan 2017 | A1 |
20170007813 | Negi et al. | Jan 2017 | A1 |
20170035331 | Parajape et al. | Feb 2017 | A1 |
20170055835 | Scherer et al. | Mar 2017 | A1 |
20170086713 | Pushpala et al. | Mar 2017 | A1 |
20170108459 | Katsuki et al. | Apr 2017 | A1 |
20170127989 | Feldman et al. | May 2017 | A1 |
20170128009 | Pushpala et al. | May 2017 | A1 |
20170164881 | Fujita et al. | Jun 2017 | A1 |
20170251959 | Feldman et al. | Sep 2017 | A1 |
20170251960 | Crouther et al. | Sep 2017 | A1 |
20170347925 | Wang et al. | Dec 2017 | A1 |
20180116572 | Simpson et al. | May 2018 | A1 |
20180140235 | Pushpala et al. | May 2018 | A1 |
20180279929 | Huang et al. | Oct 2018 | A1 |
20180317820 | Pace et al. | Nov 2018 | A1 |
20180338712 | Cass et al. | Nov 2018 | A1 |
20180340203 | Holmes et al. | Nov 2018 | A1 |
20190008425 | Srinivasan et al. | Jan 2019 | A1 |
20190022365 | Chowdhury et al. | Jan 2019 | A1 |
20190029577 | Koelker et al. | Jan 2019 | A1 |
20190090811 | Reitz et al. | Mar 2019 | A1 |
20190091455 | Reitz et al. | Mar 2019 | A1 |
20190094169 | Shah et al. | Mar 2019 | A1 |
20190101551 | Plaxco et al. | Apr 2019 | A1 |
20190110724 | Kamath et al. | Apr 2019 | A1 |
20190125223 | Wang et al. | May 2019 | A1 |
20190167167 | Mitchell et al. | Jun 2019 | A1 |
20190170739 | Garner et al. | Jun 2019 | A1 |
20190201675 | Miller et al. | Jul 2019 | A1 |
20190209095 | Kamath et al. | Jul 2019 | A1 |
20190223795 | Patolsky et al. | Jul 2019 | A1 |
20190224712 | Petisce et al. | Jul 2019 | A1 |
20190231263 | Ribet et al. | Aug 2019 | A1 |
20190241926 | Mckinlay et al. | Aug 2019 | A1 |
20190261907 | Brister et al. | Aug 2019 | A1 |
20190274599 | Polsky et al. | Sep 2019 | A1 |
20190274600 | Pesantez et al. | Sep 2019 | A1 |
20190298210 | Bennet et al. | Oct 2019 | A1 |
20190307379 | Boock et al. | Oct 2019 | A1 |
20190309433 | Sattayasamitsathit et al. | Oct 2019 | A1 |
20190310219 | Boock | Oct 2019 | A1 |
20190357827 | Li et al. | Nov 2019 | A1 |
20200000387 | Gerhardt et al. | Jan 2020 | A1 |
20200029876 | Brister et al. | Jan 2020 | A1 |
20200037938 | Rong et al. | Feb 2020 | A1 |
20200085341 | Windmiller | Mar 2020 | A1 |
20200101286 | Windmiller et al. | Apr 2020 | A1 |
20200121902 | Pushpala et al. | Apr 2020 | A1 |
20200178853 | Pushpala et al. | Jun 2020 | A1 |
20200187778 | Brister et al. | Jun 2020 | A1 |
20200214566 | Allen et al. | Jul 2020 | A1 |
20200254240 | Windmiller et al. | Aug 2020 | A1 |
20200297997 | Windmiller et al. | Sep 2020 | A1 |
20200305771 | Feldman et al. | Oct 2020 | A1 |
20200330007 | Garai et al. | Oct 2020 | A1 |
20200359949 | Brauker et al. | Nov 2020 | A1 |
20200390395 | Pushpala et al. | Dec 2020 | A1 |
20200405234 | Pushpala et al. | Dec 2020 | A1 |
20210045663 | Simpson et al. | Feb 2021 | A1 |
20210045665 | Simpson et al. | Feb 2021 | A1 |
20210045666 | Simpson et al. | Feb 2021 | A1 |
20210100452 | Brister et al. | Apr 2021 | A1 |
20210100504 | Pushpala et al. | Apr 2021 | A1 |
20210100505 | Pushpala et al. | Apr 2021 | A1 |
20210183508 | Parker et al. | Jun 2021 | A1 |
20210187286 | Windmiller et al. | Jun 2021 | A1 |
20210190719 | LaTour et al. | Jun 2021 | A1 |
20210236057 | Pushpala et al. | Aug 2021 | A1 |
20210321942 | Pushpala et al. | Oct 2021 | A1 |
20210345916 | Boock et al. | Nov 2021 | A1 |
20210353229 | Pierart et al. | Nov 2021 | A1 |
20210379370 | Windmiller et al. | Dec 2021 | A1 |
20210386338 | Zhang et al. | Dec 2021 | A1 |
20210393201 | Morelock et al. | Dec 2021 | A1 |
20220031209 | Windmiller et al. | Feb 2022 | A1 |
20220031244 | Windmiller et al. | Feb 2022 | A1 |
20220047190 | Taylor et al. | Feb 2022 | A1 |
20220054813 | Pushpala et al. | Feb 2022 | A1 |
20220054814 | Pushpala et al. | Feb 2022 | A1 |
20220104773 | Lee et al. | Apr 2022 | A1 |
20220151516 | Wang et al. | May 2022 | A1 |
20220151518 | Pushpala et al. | May 2022 | A1 |
20220151519 | Pushpala et al. | May 2022 | A1 |
20220151558 | Pushpala et al. | May 2022 | A1 |
20220175278 | Windmiller et al. | Jun 2022 | A1 |
20220175279 | Pushpala et al. | Jun 2022 | A1 |
20220175282 | Hoss et al. | Jun 2022 | A1 |
20220214300 | Wang et al. | Jul 2022 | A1 |
20220225901 | Chapman et al. | Jul 2022 | A1 |
20220233107 | Pushpala et al. | Jul 2022 | A1 |
20220249189 | Choi et al. | Aug 2022 | A1 |
20220257181 | Wang et al. | Aug 2022 | A1 |
20220298291 | Shin et al. | Sep 2022 | A1 |
20220322975 | Baker et al. | Oct 2022 | A1 |
20220322977 | Simpson et al. | Oct 2022 | A1 |
20220370011 | Windmiller et al. | Nov 2022 | A1 |
20230003725 | Wang et al. | Jan 2023 | A1 |
20230074798 | Tangney | Mar 2023 | A1 |
20230094419 | Mansfield, III et al. | Mar 2023 | A1 |
20230099617 | Mansfield, III et al. | Mar 2023 | A1 |
20230137258 | Windmiller | May 2023 | A1 |
20230190147 | Campbell et al. | Jun 2023 | A1 |
20230256220 | Mansfield et al. | Aug 2023 | A1 |
20230301552 | Mallires et al. | Sep 2023 | A1 |
20230310823 | Mansfield, III et al. | Oct 2023 | A1 |
20230414102 | Allen et al. | Dec 2023 | A1 |
20240008777 | Fuchs et al. | Jan 2024 | A1 |
20240081740 | Windmiller et al. | Mar 2024 | A1 |
20240164719 | Campbell et al. | May 2024 | A1 |
Number | Date | Country |
---|---|---|
101068591 | Nov 2007 | CN |
112617822 | Apr 2021 | CN |
113717955 | Nov 2021 | CN |
102015209669 | Dec 2016 | DE |
1006868 | Jun 2004 | EP |
1 372 602 | Apr 2007 | EP |
1792565 | Oct 2008 | EP |
1 187 653 | Mar 2010 | EP |
2 898 821 | Dec 2017 | EP |
3364183 | Aug 2018 | EP |
3 381 370 | Oct 2018 | EP |
H0222552 | Jan 1990 | JP |
H-02-031741 | Feb 1990 | JP |
H-07-275227 | Oct 1995 | JP |
2003-038464 | Feb 2003 | JP |
2003-038465 | Feb 2003 | JP |
2004180773 | Jul 2004 | JP |
2005-087613 | Apr 2005 | JP |
2006-510467 | Apr 2005 | JP |
2005-525141 | Aug 2005 | JP |
2005-322591 | Nov 2005 | JP |
2008-512162 | Apr 2008 | JP |
2008-540013 | Nov 2008 | JP |
2017108763 | Jun 2017 | JP |
2019205852 | Dec 2019 | JP |
2020170011 | Oct 2020 | JP |
2022501100 | Jan 2022 | JP |
10-2016-0108111 | Sep 2016 | KR |
WO-0074763 | Dec 2000 | WO |
WO-0074763 | Dec 2000 | WO |
WO-2006060106 | Jun 2006 | WO |
WO2006093422 | Sep 2006 | WO |
WO-2006116242 | Nov 2006 | WO |
WO-2006116242 | Nov 2006 | WO |
WO-2007040938 | Apr 2007 | WO |
WO2009034313 | Mar 2009 | WO |
WO2009064164 | May 2009 | WO |
WO-2009124095 | Oct 2009 | WO |
WO-2010014959 | Feb 2010 | WO |
WO-2010014959 | Feb 2010 | WO |
WO-2010022252 | Feb 2010 | WO |
WO-2010022252 | Feb 2010 | WO |
WO-2010045247 | Apr 2010 | WO |
WO-2010059276 | May 2010 | WO |
WO2010120364 | Oct 2010 | WO |
WO-2011056095 | May 2011 | WO |
WO2012020332 | Feb 2012 | WO |
WO-2012142625 | Oct 2012 | WO |
WO-2012142625 | Oct 2012 | WO |
WO2013058879 | Apr 2013 | WO |
WO-2014120114 | Aug 2014 | WO |
WO2015073459 | May 2015 | WO |
WO-2016189301 | Dec 2016 | WO |
WO-2017129980 | Aug 2017 | WO |
WO-2017189707 | Nov 2017 | WO |
WO-2018017196 | Jan 2018 | WO |
WO-2018071265 | Apr 2018 | WO |
WO-2018170363 | Sep 2018 | WO |
WO2018164886 | Sep 2018 | WO |
WO-2019046333 | Mar 2019 | WO |
WO-2019156934 | Aug 2019 | WO |
WO-2019222615 | Nov 2019 | WO |
WO-2019239258 | Dec 2019 | WO |
WO-2020023804 | Jan 2020 | WO |
WO-2020117918 | Jun 2020 | WO |
WO-2021015389 | Jan 2021 | WO |
WO-2021025260 | Feb 2021 | WO |
WO-2021062475 | Apr 2021 | WO |
WO-2021086690 | May 2021 | WO |
WO-2021118124 | Jun 2021 | WO |
WO-2021118431 | Jun 2021 | WO |
WO-2021216186 | Oct 2021 | WO |
WO-2021216186 | Dec 2021 | WO |
WO-2022026764 | Feb 2022 | WO |
WO-2022066985 | Mar 2022 | WO |
WO-2022066992 | Mar 2022 | WO |
WO-2022090741 | May 2022 | WO |
WO-2022136785 | Jun 2022 | WO |
WO-2022240700 | Nov 2022 | WO |
WO-2023055755 | Apr 2023 | WO |
WO-2023064877 | Apr 2023 | WO |
WO-2023133468 | Jul 2023 | WO |
WO-2023229662 | Nov 2023 | WO |
WO-2024010827 | Jan 2024 | WO |
Entry |
---|
Bantle, J.P. et al. (1997). “Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid,” J. Lab. Clin. Med. 130:436-441. |
Beckles, G.L. et al. (2016). “Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014,” MMWR 65:1265-1269. |
Castle, J.R. et al. (2012). “The accuracy benefit of multiple amperometric glucose sensors in people (with type 1 diabetes,” Diabetes Care 35:706-710. |
Chang, H. et al. (2017). “A swellable microneedle patch to rapidly extract skin interstitial fluid for timely metabolic analysis,” Adv. Mater. 29:1702243. |
Dexcom (2020). Analyst Day Presentation, 27 total pages. |
Dexcom (2020). Analyst Day Presentation, 19 total pages. |
Diabetes Care (2021). “7. Diabetes Technology: Standards of Medical Care in Diabetes—2021,” Diabetes Care 44(Supplement 1):S85-S99. |
Donnelly, R.F. et al. (2007). “Microstructured Devices for Transdermal Drug Delivery and Minimally-Invasive Patient Monitoring,” Recent Patents on Drug Delivery & Formulation 1:195-200. |
Extended European Search Report mailed on May 8, 2015, for EP Application No. 12 842 020.5, filed on Aug. 31, 2012, 7 pages. |
Fang, M. et al. (2021). “Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018,” N. Engl. Med. 384:2219-2228. |
Final Office Action mailed on Aug. 19, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages. |
Final Office Action mailed on Nov. 28, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 34 pages. |
Final Office Action mailed on May 18, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 23 pages. |
Final Office Action mailed on Dec. 7, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages. |
Final Office Action mailed on May 21, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 11 pages. |
Final Office Action mailed on Jun. 9, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 24 pages. |
French, D.P. et al. (2008). “Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial,” Diav. Med. 25:1218-1228. |
Gittard, S.D. et al. (2009). “Fabrication of Polymer Microneedles Using a Two-Photon Polymerization Jand Micromolding Process,” J. Diabetes Sci. Technol. 3:304-311. |
Grady, M. et al. (2017). “Examining the Impact of a Novel Blood Glucose Monitor With Color Range Indicator on Decision-Making in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level,” JMIR Diabetes 2:e24. |
Grady, M. et al. (2018). “Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients With Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study),” J. Diab. Sci. Tech. 12:1211-1219. |
Groenendaal, W. et al. (2008). “Modeling Glucose and Water Dynamics in Human Skin,” Diab. Tech. Therap. 10:283-293. |
International Search Report malled on Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 2 pages. |
International Search Report mailed on Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 2 pages. |
International Search Report mailed on Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 7 pages. |
International Search Report mailed on Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 4 pages. |
Jeon, G. et al. (2011). “Electrically Actuatable Smart Nanoporous Membrane for Pulsatile Drug Release,” Nano Lett. 11:1284-1288. |
Jina, A et al. (2014). “Design, development, and evaluation of a novel microneedle array-based continuous glucose monitor,” J. Diabetes Sci. Technol. 8:483-487. |
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes,” N. Engl. Med. 359:1464-1476. |
Karter, A.J. et al. (2021). “Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes,” JAMA 325:2273-2284. |
Lhernould, M.S. et al. (2015). “Review of Patents for Microneedle Application Devices Allowing Fluid Injections Through the Skin,” Recent Patents on Drug Delivery & Formulation 9:146-157. |
Malitesta et al. (1990), “Glucose fast-response amperometric sensor based on glucose oxidase immobilized in an electropolymerized poly(o-phenylenediamine) film,” Anal. Chem. 62:2735-2740. |
Martens, T. et al. (2021). “Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin A Randomized Clinical Trial,” JAMA 325:2262-2272. |
McClatchey, P.M. et al. (2019). “Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays,” Diabetes 68:1892-1901. |
Miller, P.R. et al. (2011). “Integrated carbon fiber electrodes within hollow polymer microneedles for transdermal electrochemical sensing,” BioMicrofluidics 5(1):013415. |
Neerken, S. et al. (2004). “Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography,” J. Biomed. Optics 9:274-281. |
Non-Final Office Action mailed on Mar. 10, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 15 pages. |
Non-Final Office Action mailed on Mar. 30, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 31 pages. |
Non-Final Office Action mailed on Mar. 9, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages. |
Non-Final Office Action mailed on Apr. 6, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 32 pages. |
Non-Final Office Action mailed on Nov. 1, 2017, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 19 pages. |
Non-Final Office Action mailed on Jan. 19, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 11 pages. |
Non-Final Office Action mailed on Apr. 13, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages. |
Non-Final Office Action mailed on Sep. 3, 2020, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 19 pages. |
Non-Final Office Action mailed on Oct. 16, 2020, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 13 pages. |
Non-Final Office Action mailed on Nov. 4, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 20 pages. |
Non-Final Office Action mailed on Nov. 26, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages. |
Non-Final Office Action mailed on Nov. 29, 2021, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 14 pages. |
Notice of Allowance mailed on Jul. 6, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 12 pages. |
Notice of Allowance mailed on Jul. 12, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 14 pages. |
Notice of Allowance mailed on Feb. 13, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 8 pages. |
Notice of Allowance mailed on Aug. 24, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 7 pages. |
Notice of Allowance mailed on May 25, 2021, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 11 pages. |
Rigla, M. et al. (2018). “Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy,” Diabetes Technology & Therapeutics 20:296-302. |
Sachdeva, V. et al. (2011). “Microneedles and their applications,” Recent Patents on Drug Delivery & Formulation 5:95-132. |
Sheikh, Z. et al. (2015). “Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials,” Materials 8:5671-5701. |
Shi, T. et al. (2016). “Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes,” J. Diab. Res. vol. 2016, 9 pages. |
Singh, T.R.R. et al. (2010). “Microporation techniques for enhanced delivery of therapeutic agents,” Recent Patents on Drug Delivery & Formulation 4:1-17. |
Texas Instruments (Sep. 2007). Data sheet for a LMP2234 quad micropower, 1.6V, precision, operational amplifier with CMOS input, Sep. 2007, revised Mar. 2013. |
Windmiller, J.R. (2012). “Molecular scale biocomputing: An enzyme logic approach,” University of California, San Diego, A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Electrical Engineering (Photonics), 78 total pages. |
Windmiller, J.R. et al. (2011). “Bicomponent microneedle array biosensor for minimally-invasive glutamate monitoring,” Electroanalysis 23:2302-2309. |
Windmiller, J.R. et al. (2011). “Microneedle array-based carbon paste amperometric sensors and blosensors,” Analyst 136:1846-1851. |
Written Opinion of the International Searching Authority mailed on Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 5 pages. |
Written Opinion of the International Searching Authority mailed on Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 4 pages. |
Written Opinion of the International Searching Authority mailed on Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 10 pages. |
Written Opinion of the International Searching Authority mailed on Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 15 pages. |
Yoon, Y. et al. (2013). “Fabrication of a Microneedle/CNT Hierarchical Micro/Nano Surface Electrochemical Sensor and Its In-Vitro Glucose Sensing Characterization,” Sensors 13:16672-16681. |
Abbot press release (2020). “New late-breaking data show use of abbott's Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not,” 3 pages. |
American Diabetes Association® Press Release (2020). “American Diabetes Association® Applauds policymakers' Focus on Addressing High Costs of Insulin for Seven Million Americans,” 4 pages. |
Cao, J. et al. (2017). “Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system,” Pract. Lab. Med. 9:24-27. |
Final Office Action mailed on May 9, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 17 pages. |
Final Office Action mailed on Aug. 15, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages. |
International Search Report mailed on Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 2 pages. |
Non-Final Office Action mailed on Apr. 8, 2022, for U.S. Appl. No. 17/650,056, filed Feb. 4, 2022, 14 pages. |
Notice of Allowance mailed on Sep. 12, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 8 pages. |
Polonsky, W.H. et al. (2011). “A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?” Curr. Med. Res. & Opinion 27:31-37. |
Written Opinion of the International Searching Authority mailed on Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 5 pages. |
Extended European Search Report mailed on Oct. 27, 2022, for EP Application No. 21 850 331.6, filed on Jul. 29, 2021, 8 pages. |
International Search Report mailed on Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages. |
Mohan, A.M. (2017). “Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays,” Biosensors and Bioelectronics 91:574-579. |
Non-Final Office Action mailed on Dec. 21, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 12 pages. |
Non-Final Office Action mailed on Jan. 27, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 15 pages. |
Non-Final Office Action mailed on Feb. 16, 2023, for U.S. Appl. No. 17/738,990, 8 pages. |
Non-Final Office Action mailed on Mar. 9, 2023, for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 24 pages. |
Swedish Search Report mailed on Feb. 3, 2023 for SE Application No. 2350067-1, 7 pages. |
Written Opinion of the International Searching Authority mailed on Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages. |
Al Hayek et al., “Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study” Cureus Oct. 27, 2020; 12(10):e11195. 8 pages. |
Allen et al., “Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial” Diabetes Res Clin Pract. Jun. 2008; 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006. |
Barrett et al., “Risk for Newly Diagnosed Diabetes 30 Days After SARS-CoV-2 Infection Among Persons Aged 18 Years—United States, Mar. 1, 2020-Jun. 28, 2021” MMWR Morb Mortal Wkly Rep. Jan. 14, 2022; 71(2):59-65. doi: 10.15585/mmwr.mm7102e2. |
Brown, “Design of Electronics for Wearable Electrochemical Sensors” University of California, San Diego, Master's Thesis (2019) 48 pages. |
Centers for Disease Control, “National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States” (2020) 32 pages. |
Dunkin et al., “Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers” Plast Reconstr Surg. May 2007; 119(6): 1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0. |
Ehrhardt et al., “Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring ” Journal of Diabetes Science and Technology Mar. 2019; 13(2):271-275. |
Ehrhardt et al., “Continuous Glucose Monitoring As a Behavior Modification Tool” Clin Diabetes. Apr. 2020; 38(2):126-131. doi: 10.2337/cd19-0037. |
Ehrhardt et al., “The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus” Journal of Diabetes Science and Technology May 2011; 5(3):668-675. |
Extended European Search Report mailed on Mar. 30, 2023, for European Application No. EP20881425.1, 8 pages. |
Final Office Action mailed on Aug. 29, 2023, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 17 pages. |
Fonda et al., “The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes” Journal of Diabetes Science and Technology (2016) 10(4):898-904. |
Han et al., “The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?” Journal of Diabetes Science and Technology (2020) 14(3):595-600. |
Han et al., “The YSI 2300 Analyzer Replacement Meeting Report” Journal of Diabetes Science and Technology (2020) 14(3):679-686. |
Non-Final Office Action mailed on May 24, 2023, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 19 pages. |
Non-Final Office Action mailed on Jun. 2, 2023, for U.S. Appl. No. 17/367,274, filed Jul. 2, 2021, 27 pages. |
Non-Final Office Action mailed on Jun. 20, 2023, for U.S. Appl. No. 17/073,331, filed Oct. 17, 2020, 10 pages. |
Non-Final Office Action mailed on Sep. 15, 2023, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 12 pages. |
Notice of Allowance mailed on Jun. 12, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 14 pages. |
Notice of Allowance mailed on Jun. 12, 2023, for U.S. Appl. No. 17/738,990, filed May 6, 2022, 7 pages. |
Notice of Allowance mailed on Sep. 25, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 8 pages. |
Notice of Allowance mailed on Sep. 26, 2023, for U.S. Appl. No. 17/738,990, filed May 6, 2022, 7 pages. |
Sharifi et al., “Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring” Journal of Diabetes Science and Technology (2016) 10(3):669-678. |
Turner et al., “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)” The Lancet Sep. 1998; 352(9131):837-853. |
Vigersky et al., “Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes” Diabetes Care Jan. 2012; 35:32-38. |
Wolicki et al., “Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration” Centers for Disease Control and Prevention (2021) 17 pages. |
World Health Organization, “Diabetes”, Sep. 16, 2022, 5 pages. |
Young et al., “Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial” JAMA Intern Med. Jul. 2017; 177(7):920-929. |
American Diabetes Association, “Diabetes and Emotional Health: A Practical Guide for Health Professionals Supporting Adults with Type 1 and Type 2 Diabetes” U.S. Edition (2021), 214 pages. |
American Diabetes Association Professional Practice Committee, “6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024” Diabetes Care Jan. 1, 2024; 47(Suppl 1):S111-S125. |
American Diabetes Association Professional Practice Committee, “7. Diabetes Technology: Standards of Medical Care in Diabetes—2022” Diabetes Care Jan. 1, 2022; 45(Suppl 1):S97-S112. |
Chen et al., “Electrochemically Mediated Electrodeposition/Electropolymerization To Yield a Glucose Microbiosensor with Improved Characteristics” Anal. Chem. (2002) 74:368-372. |
Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus” N Engl J Med Sep. 30, 1993; 329(14):977-986. |
Elsayed et al., “2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023” Diabetes Care Jan. 1, 2023; 46(Suppl 1):S19-S40. |
Extended European Search Report for European Application No. EP20898007.8 dated Nov. 29, 2023, 9 pages. |
Final Office Action mailed on Feb. 1, 2024, for U.S. Appl. No. 17/073,331, filed Oct. 17, 2020, 12 pages. |
Final Office Action mailed on Feb. 8, 2024, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages. |
Final Office Action mailed on Mar. 15, 2024, for U.S. Appl. No. 17/367,274, filed Jul. 2, 2021, 33 pages. |
Final Office Action mailed on Nov. 27, 2023, for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 29 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2020/064700, mail date Mar. 9, 2021, 11 pages. |
International Search Report and Written Opinion mailed on Feb. 6, 2024, for International Application No. PCT/US2022/078819, filed on Oct. 27, 2022, 13 pages. |
Mendes-Soares et al., “Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes” JAMA Network Open Feb. 1, 2019; 2(2):e188102. 13 pages. |
Miller et al., “Hypoglycemia in patients with type 2 diabetes mellitus” Arch Intern Med Jul. 9, 2001; 161(13):1653-1659. |
Newton et al., “Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences” Arch Intern Med Sep. 27, 2004; 164(17):1925-1931. |
Non-Final Office Action mailed on Apr. 16, 2024, for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 28 pages. |
Non-Final Office Action mailed on Dec. 13, 2023, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 16 pages. |
Notice of Allowance (Corrected) mailed on Apr. 19, 2024, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 4 pages. |
Notice of Allowance (Corrected) mailed on Jan. 25, 2024, for U.S. Appl. No. 17/349,234, filed Jun. 16, 2021, 4 pages. |
Notice of Allowance (Corrected) mailed on Mar. 18, 2024, for U.S. Appl. No. 17/349,234, filed Jun. 16, 2021, 9 pages. |
Notice of Allowance mailed on Apr. 10, 2024, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 10 pages. |
Notice of Allowance mailed on Dec. 20, 2023, for U.S. Appl. No. 17/349,234, filed Jun. 16, 2021, 13 pages. |
Notice of Allowance mailed on Mar. 21, 2024, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 6 pages. |
Notice of Allowance mailed on Mar. 4, 2024, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 10 pages. |
Office Action and Swedish Search Report mailed on Oct. 17, 2023, for SE Application No. 2251496-2, 8 pages. |
Segel et al., “Hypoglycemia-associated autonomic failure in advanced type 2 diabetes” Diabetes Mar. 2002; 51(3):724-733. |
Shivers et al., “Turn it off!: diabetes device alarm fatigue considerations for the present and the future” J Diabetes Sci Technol May 1, 2013; 7(3):789-794. |
Supplementary European Search Report mailed on Oct. 9, 2023, for EP Application No. 22808101.4, 4 pages. |
Tanenbaum et al., “Diabetes Device Use in Adults With Type 1 Diabetes: Barriers to Uptake and Potential Intervention Targets” Diabetes Care Feb. 2017; 40(2):181-187. |
UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)” Lancet Sep. 12, 1998; 352(9131):837-853. |
Non-Final Office Action mailed on May 24, 2024, for U.S. Appl. No. 18/527,128, filed Dec. 1, 2023, 17 pages. |
Number | Date | Country | |
---|---|---|---|
62470204 | Mar 2017 | US |